AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer

NEXT STORY
Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19
PREV STORY
Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board

author_avatar
NASDAQ Market News

Ventilator Market to Reach USD 9.13 Billion by 2027; Surging Number of Critical Cases Owing to COVID-19 will Boost Growth, says Fortune Business Insights™

author_avatar
NASDAQ Market News

Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer – The primary endpoint was met

ORION CORPORATION        STOCK EXCHANGE RELEASE         24  OCTOBER 2018 AT  8.30  a.m. EEST Orion and ...

author_avatar
NASDAQ Market News